Optimizing antibiotic-related outcomes in the critically Ill patient

Infectious Diseases in Clinical Practice

Volumn 13, Issue 4, 2005, Pages 158-164

  Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBENICILLIN; CEFAMANDOLE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CRITICAL ILLNESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG COST; DRUG POTENCY; DRUG SENSITIVITY; DRUG STABILITY; GRAM NEGATIVE INFECTION; GRANULOCYTOPENIA; HOSPITAL INFECTION; HUMAN; INFECTION; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORBIDITY; MORTALITY; PHARMACODYNAMICS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME;

EID: 22644434141     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000168479.11589.9d     Document Type: Review

References (34)

1. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146-155.
2. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000;31: S131-S138.
3. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-268.
4. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-12.
5. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother. 1997;9:38-44.
6. Drusano G, Labro MT, Cars O, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect. 1998;4:S27-S41.
7. Bradley JS, Dudley MA, Drusano GL. Predicting efficacy of antibiotics with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003;22:982-992.
8. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
9. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
10. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia cause by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623-629.
11. Tumidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998;27:10-22.
12. Kuti JL, Maglio D, Nightingale CH, et al. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm. 2003;60:565-568.
13. Dandekar PK, Maglio D, Sutherland CA, et al. Pharmacokinetic profile of meropenem 0.5g and 2g administered as a 3 hour infusion. Pharmacotherapy. 2003;23:988-991.
14. Kuti JL, Dandekar PK, Nightingale CH, et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategies for meropenem. J Clin Pharmacol. 2003;43:1116-1123.
15. Nicolau DP, Nightingale CH, Quintiliani R. Continuous infusion β-lactams: a pharmacodynamic approach. Infect Dis Clin Pract. 1996;5:432-434.
16. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med. 1979;67:608-616.
17. Nicolau DP, McNabb JC, Lacy MK, et al. Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumonia. Clin Drug Invest. 1999;18:133-139.
18. Nicolau DP, McNabb JC, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents. 2001;17:497-504.
19. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002;22:471-483.
20. Kuti JL, Moss KM, Nicolau DP, et al. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy. 2004;24:1641-1645.
21. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669-683.
22. Forrest A, Nix DE, Sallow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
23. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolones area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004;189:1590-1597.
24. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother. 2004;48:2464-2470.
25. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999;43:672-677.
26. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45:2793-2797.
27. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med. 2001;111:13S-18S, discussion 36S-38S.
28. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747-750.
29. Grant EM, Nicolau DP. Pharmacodynamic considerations in the selection of antibiotics for respiratory tract infections: focus on the fluoroquinolones. Antibiot Clin. 1999;3:21-28.
30. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
31. Davies TA, Evangelista A, Pfleger S, et al. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother. 2002;46:119-124.
32. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in the United States since 1994-1995. Antimicrob Agents Chemother. 2002;46:680-688.
33. Capitano B, Mattoes HM, Shore E, et al. Steady state intrapulmonary concentrations of moxifloxacin, levofloxacin and azithromycin in older adults. Chest. 2004;125:965-973.
34. Florea NR, Tessier PR, Zhang C, et al. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2004;48:1215-1221.